Merck Group
USA · Pharma & Healthcare
LeaveRussia detail: Pausing Investments
Merck is the premier research-intensive biopharmaceutical company in the world, research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.
Decision trail
Decision date 28/03/2022 · Reference ↗
Suspended future investments with Russia. Continuing to supply medicines and vaccines. (No research or production facilities in Russia)
Local stats (LeaveRussia)
Assets(RF), mln.USD
236
Capital(RF), mln.USD
166
Glob.Revenue, mln.USD
59283
Revenue(RF), mln.USD
272
Staff(RF), 2021
441
Taxes(RF), mln.USD
2
Status history since 2022
- 03/08/2026 — suspended · Imported from KSE LeaveRussia
Exposure profile
Full exposure profile is a Professional feature
Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.
Upgrade to Professional